Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

Official record

Identifier

NCT06447636

Recruiting locations

country

China

Interventions studied

SurufatinibSintilimabOxaliplatinS1

Lead sponsor

Fudan University

Target enrolment

20 participants

Study type

INTERVENTIONAL

Phase

Phase 2

Status

Active, not recruiting

First posted

Jun 7, 2024

Last updated on the registry

Aug 5, 2026

Age

18 Years – 75 Years

Sex

ALL

Study contact

No public contact is listed on the official record.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* signed informed consent
* patients age 18-75 years;
* Histologically CT/MRI confirmed cT3-4bNanyM0 gastric or GEJ adenocarcinoma;
* ECOG 0-1, no surgery contraindications;
* Expected survival ≥3 months;

Exclusion Criteria:

* signs of distant metastases
* Prior chemotherapy, radiotherapy, surgery for gastric cancer;
* Significant cardiovascular disease
* major surgical procedure within 4 weeks prior to initiation of study treatment
* current treatment with anti-viral therapy or HBV
* pregnancy or breastfeeding
* history of malignancy within 5 years prior to screening
* Present or history of any autoimmune disease or immune deficiency;
* Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent;
* There are active gastric and duodenal ulcers, ulcerative colitis and other gastrointestinal diseases, or active bleeding in unresectable tumors.
* Poorly controlled hypertension or diabetes;

Indexed under

Esophageal Cancer